Polyphor and EnBiotix to Merge, Plan Trials in 2 Lung Infection Therapies

Polyphor and EnBiotix to Merge, Plan Trials in 2 Lung Infection Therapies

304907

Polyphor and EnBiotix to Merge, Plan Trials in 2 Lung Infection Therapies

EnBiotix has purchased murepavadin, an investigational inhaled antibiotic to treat Pseudomonas aeruginosa infections in people with cystic fibrosis (CF), from Polyphor. The two companies also entered into an agreement to merge, wherein Polyphor will acquire all EnBiotix stock in exchange for Polyphor stock newly issued upon closing. The merger is expected to close by year’s end, assuming the agreement is approved by both companies’ shareholders, as well as assessment of tax consequences and other conditions. Once established, the newly…

You must be logged in to read/download the full post.